To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year.
Lilly will take on a manufacturing site in Pleasant Prairie, WI, along with its workers for an undisclosed amount. The 84,000 square-foot building opened in 2021, and commercial production started in 2023, with Nexus spending over $100 million on the facility, according to Nexus’ website.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.